Last update 25 Nov 2024
ADC-2122
Last update 25 Nov 2024
Overview
Basic Info
Drug Type Antibody drug conjugate (ADC) |
Synonyms Recombinant Humanized Anti-Human Epidermal Growth Factor Receptor Monoclonal Antibody and the Dolastatins Derivative DUO5 Conjugated, ADC-2122, ZV0203 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 18492L
The sequence is quoted from: *****
Sequence Code 18505H
The sequence is quoted from: *****
Related
2
Clinical Trials associated with ADC-2122An Open-label, Multicenter, Phase I Dose-escalation Study to Assess the Safety, Pharmacokinetic (PK), Immunogenicity and Preliminary Anti-tumor Activity of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
一项在表达 HER2 的晚期实体瘤患者中评估 ZV0203 的安全性、药代动力学、免疫原性及其初步抗肿瘤活性的开放、多中心的 1 期剂量递增研究
[Translation] An open-label, multicenter, phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, immunogenicity, and preliminary antitumor activity of ZV0203 in patients with advanced HER2-expressing solid tumors
100 Clinical Results associated with ADC-2122
Login to view more data
100 Translational Medicine associated with ADC-2122
Login to view more data
100 Patents (Medical) associated with ADC-2122
Login to view more data
100 Deals associated with ADC-2122
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 17 Dec 2021 | |
| HER2 Positive Solid Tumors | Phase 1 | CN | 17 Dec 2021 | |
| HER2 Positive Solid Tumors | Phase 1 | CN | 17 Dec 2021 | |
| HER2 Positive Solid Tumors | Phase 1 | CN | 17 Dec 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT05423977 (ESMO2023) Manual  | Phase 1 | HER2 Positive Solid Tumors HER2 positive | 15 | zwabgnppav(hlpeujhjta) = iwxvtlnyxb bxugjwpwvl (kybcvxzikr ) View more | Positive | 21 Oct 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free